The anticipation of a positive label determination in Europe for Esperion's cardiovascular risk reduction product could lead to increased investor optimism. This optimism is based on the potential for expanded market access and revenue streams in Europe, which are critical factors for the company's growth. However, the actual impact will depend on the final decision and the company's ability to capitalize on this opportunity.